- Yale Medicine, Digestive Diseases325 Riverside Ave325 Riverside AvenueWestport, CT 06880
- Yale Medicine, Digestive DiseasesYale Bariatric and Minimally Invasive Surgery2000 Post RoadFairfield, CT 06824
Vikas Gupta, MD, PhD
Biography
Vikas Gupta, MD, PhD, is a gastroenterologist who specializes in liver disease and medical weight loss management.
Growing up, Dr. Gupta had a unique perspective of medical education and training. His father switched careers and entered medical school when Dr. Gupta was about 7. “He wasn’t a full-fledged physician until I was in high school, and I got to watch the whole process,” he says. “It struck me as an intellectually interesting and rewarding career path.”
After medical school, Dr. Gupta considered specializing in cardiology, but during internal medical training, his exposure to patients with end-stage liver disease changed his mind.
“I found the physiology of this patient population really interesting and saw opportunities for clinical improvement,” he says. “When your liver doesn’t function well, it can affect your lungs, heart, kidneys, gastrointestinal tract, skin, and brain. By taking care of patients with liver disease, it keeps me thinking about the physiology of all organs.”
As clinical director of the Fatty Liver Disease Program, Dr. Gupta says a major piece of his job is medical weight management. “We are seeing so many patients with liver abnormalities that stem from fatty liver disease that we know will improve with weight loss,” he says. “We have a great team and resources to help patients achieve their weight loss goals. We want to help patients with fatty liver disease avoid developing end-stage liver disease.”
In the clinic, Dr. Gupta likes to keep it simple, “In medical training, we learn so much jargon that is not useful to patients,” he says. “I try to draw diagrams and simplify the terminology to make it easier for patients to understand.”
Titles
- Assistant Professor of Medicine (Digestive Diseases) and of Pathology
- Clinical Director of Yale Fatty Liver Disease Program, Internal Medicine
Education & Training
- FellowshipWeill Cornell Medical College (2020)
- ResidencyMassachusetts General Hospital (2016)
- InternshipMassachusetts General Hospital (2015)
- PhDDuke University School of Medicine (2014)
- MDDuke University School of Medicine (2014)
- BSPennsylvania State University, Biology (2007)
Additional Information
- Junior Faculty Samuel Kushlan Award: (2023)
- Early Career Investigator in Basic Science: AASLD (2020)
- Kellen Fellowship: (2019)
- Cani L, Gupta V, Kaufman J. BCL2 inhibition for multiple myeloma and AL amyloidosis. British Journal Of Haematology 2025 PMID: 40090369, DOI: 10.1111/bjh.20046.
- Nair R, Vu A, Freer A, Bhatia K, Wang D, Savani M, Matulis S, Lonial S, Jaye D, Boise L, Seo S, Corson T, Nooka A, Bhatt S, McBrayer S, Gupta V, Hu X, Barwick B, Reddi A, Shanmugam M. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood 2025, 145: 732-747. PMID: 39693611, DOI: 10.1182/blood.2024025690.
- Potdar S, Kapadia S, Azeem M, Radzievski R, Lakhani K, Joseph N, Kaufman J, Hofmeister C, Gupta V, Lonial S, Nooka A, Dhodapkar K, Dhodapkar M. Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myeloma. Blood Advances 2025 PMID: 39913930, DOI: 10.1182/bloodadvances.2024015680.
- Dutta R, Thibaud S, Leshchenko V, Ram M, Melnekoff D, Bhalla S, Restrepo P, Gupta V, Barwick B, Newman S, McCafferty J, Hantash F, Nooka A, Cho H, Richard S, Rodriguez C, Rossi A, Sanchez L, Chari A, Boise L, Jagannath S, Richter J, Parekh S, Laganà A. Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma. Blood Neoplasia 2024, 1: 100049. DOI: 10.1016/j.bneo.2024.100049.
- Bollinger B, Cotter R, Deng Y, Ilagan-Ying Y, Gupta V. Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease. Digestive Diseases And Sciences 2024, 70: 378-385. PMID: 39604664, DOI: 10.1007/s10620-024-08724-y.
- Joseph N, Gupta S, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A. Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 7870-7870. DOI: 10.1182/blood-2024-211988.
- Gu L, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 3780. DOI: 10.1182/blood-2024-211474.
- Allada S, Gupta V, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Joseph N. Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers. Blood 2024, 144: 7861. DOI: 10.1182/blood-2024-210996.
- Matulis S, Chavez R, Owens R, Wiita A, Shanmugam M, De Matos Simoes R, Mitsiades C, Joseph N, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Gupta V, Licht J, Barwick B, Boise L. Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2. Blood 2024, 144: 4663-4663. DOI: 10.1182/blood-2024-210441.
- Joseph N, Kaufman J, Hofmeister C, Gupta V, Burton B, Pruitt R, Nooka A, Dhodapkar M, Lonial S. Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM). Blood 2024, 144: 1983-1983. DOI: 10.1182/blood-2024-210335.
- Cani L, Scott S, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies. Blood 2024, 144: 3311. DOI: 10.1182/blood-2024-206155.
- Shivaram S, Yan H, Tang H, Anderson H, Kaddoura M, Wiedmeier-Nutor J, Tian S, Howe M, Bolarinwa A, Zepeda Mendoza C, Gupta V, Lehman S, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Maura F, Kumar S, Baughn L. The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma. Blood 2024, 144: 4635-4635. DOI: 10.1182/blood-2024-205385.
- Varga C, Robinson M, Gupta V, Hofmeister C, Nooka A, Kaufman J, Dhodapkar M, Lonial S, Borden S, Ferreri C, Paul B, Atrash S, Bhutani M, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes. Blood 2024, 144: 4702-4702. DOI: 10.1182/blood-2024-204388.
- Kaddoura M, Wiedmeier-Nutor J, Gupta V, Ziccheddu B, Shivaram S, Tang H, Fonseca R, Durante M, Matulis S, Jelinek T, Landgren O, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Kumar S, Maura F, Baughn L. Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax. Blood 2024, 144: 249. DOI: 10.1182/blood-2024-204071.
- Hofmeister C, Gupta V, Joseph N, Lonial S, Dhodapkar M, Nooka A, Kaufman J. A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy. Blood 2024, 144: 4672. DOI: 10.1182/blood-2024-203485.
- Hofmeister C, Gupta V, Kaufman J, Nooka A, Joseph N, Lonial S, Dhodapkar M. A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma. Blood 2024, 144: 255-255. DOI: 10.1182/blood-2024-202102.
- Hofmeister C, Zhang M, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Sborov D. Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting. Blood 2024, 144: 5152-5152. DOI: 10.1182/blood-2024-202100.
- Najarro G, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Hofmeister C. Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade. Blood 2024, 144: 5142-5142. DOI: 10.1182/blood-2024-202078.
- Householder S, Loza A, Gupta V, Doolittle B. Using Panel Management to Identify Adult Patients With High-Risk Metabolic Dysfunction–Associated Steatotic Liver Disease/Metabolic Dysfunction–Associated Steatohepatitis Fibrosis in a Primary Care Clinic: A Pilot Study. The Permanente Journal 2024, 28: 38-47. PMID: 39444281, PMCID: PMC11648331, DOI: 10.7812/tpp/24.094.
- Matulis S, Barwick B, Bombin S, Ackley J, Gupta V, Hill G, Green D, Riddell S, Lonial S, Dhodapkar M, Boise L. P-234 Autocrine IL6 Signaling in Stromal Cells in Multiple Myeloma Influences the Bone Marrow Microenvironment. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s173. DOI: 10.1016/s2152-2650(24)02137-2.
- Morffi R, Pruitt R, Nguyen K, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Kaufman J, Nooka A. P-179 Rates of Successful Diagnostic Clonal Identification (ID) With Adaptive clonoSEQ®. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s141-s142. DOI: 10.1016/s2152-2650(24)02082-2.
- Joseph N, Pruitt R, Gupta V, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Kaufman J. P-342 Impact of Achieving
DOI: 10.1016/s2152-2650(24)02244-4. - Joseph N, Kaufman J, Gupta V, Hofmeister C, Dhodapkar M, Scott S, Dicamillo S, Roberts D, Lonial S, Nooka A. OA-51 Efficacy of Dara-RVD Induction Therapy in Newly Diagnosed Myeloma (NDMM) Patients ≥65 Years of Age. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s32. DOI: 10.1016/s2152-2650(24)01892-5.
- Scott S, Roberts D, Gupta V, Joseph N, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. NSO-06 Protocol for Outpatient Administration of Multiple Myeloma Bispecific Antibodies Step-Up Dosing. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s282. DOI: 10.1016/s2152-2650(24)02331-0.
- Varga C, Robinson M, Ehsan H, Roberts D, Dicamillo S, Gupta V, Borden S, Bhutani M, Paul B, Atrash S, Ferreri C, Nooka A, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience. Transplantation And Cellular Therapy 2024, 30: s377-s378. DOI: 10.1016/j.jtct.2023.12.528.
- Singh S, Budiman T, Redmond D, Gupta V. Modulation of canonical Wnt signaling regulates peribiliary mesenchymal identity during homeostasis and injury. Hepatology Communications 2024, 8: e0368. PMID: 38251878, PMCID: PMC10805418, DOI: 10.1097/hc9.0000000000000368.
- Scott S, Marin E, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer Journal 2023, 13: 191. PMID: 38114481, PMCID: PMC10730907, DOI: 10.1038/s41408-023-00963-y.
- Juarez D, Buono R, Matulis S, Gupta V, Duong M, Yudiono J, Paul M, Mallya S, Diep G, Hsin P, Lu A, Suh S, Dong V, Roberts A, Leverson J, Jalaluddin M, Liu Z, Bueno O, Boise L, Fruman D. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitors. Cancer Research Communications 2023, 3: 2497-2509. PMID: 37956312, PMCID: PMC10704957, DOI: 10.1158/2767-9764.crc-23-0350.
- Lewis J, Shebelut C, Attieh M, Horwath M, Khanna A, Al-Rusan O, Ponnatt T, Smith G, Gutman D, Gupta V, Aljudi A, Cooper L, Jaye D. Machine Learning Models Predict Molecular Genetic Subtypes of Multiple Myeloma from Whole-Slide Bone Marrow Aspirate Smears. Blood 2023, 142: 7158. DOI: 10.1182/blood-2023-190686.
- Kaufman J, Joseph N, Gupta V, Dicamillo S, Roberts D, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Boise L. Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma. Blood 2023, 142: 4699. DOI: 10.1182/blood-2023-181783.
- Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.
- Nooka A, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Burton B, Ahmed H, Linton D, Cortoos A, Lin T, Labotka R, Noga S, Kaufman J, Lonial S. A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study. Blood 2023, 142: 4764. DOI: 10.1182/blood-2023-190871.
- Marin E, Scott S, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration. Blood 2023, 142: 2008. DOI: 10.1182/blood-2023-189878.
- Singh S, Lian Q, Budiman T, Taketo M, Simons B, Gupta V. Heterogeneous murine peribiliary glands orchestrate compartmentalized epithelial renewal. Developmental Cell 2023, 58: 2732-2745.e5. PMID: 37909044, PMCID: PMC10842076, DOI: 10.1016/j.devcel.2023.10.004.
- Bram Y, Nguyen DT, Gupta V, Park J, Richardson C, Chandar V, Schwartz RE. Cell and Tissue Therapy for the Treatment of Chronic Liver Disease. Annual Review Of Biomedical Engineering 2021, 23: 1-30. PMID: 33974812, PMCID: PMC8864721, DOI: 10.1146/annurev-bioeng-112619-044026.
- Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, Tang X, Zhu J, Zhao Z, Jaffré F, Zhang T, Kim TW, Harschnitz O, Redmond D, Houghton S, Liu C, Naji A, Ciceri G, Guttikonda S, Bram Y, Nguyen DT, Cioffi M, Chandar V, Hoagland DA, Huang Y, Xiang J, Wang H, Lyden D, Borczuk A, Chen HJ, Studer L, Pan FC, Ho DD, tenOever BR, Evans T, Schwartz RE, Chen S. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell 2020, 27: 125-136.e7. PMID: 32579880, PMCID: PMC7303620, DOI: 10.1016/j.stem.2020.06.015.
- Gupta V, Gupta I, Park J, Bram Y, Schwartz RE. Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells. Gastroenterology 2020, 159: 624-638.e9. PMID: 32289375, PMCID: PMC8204800, DOI: 10.1053/j.gastro.2020.03.075.
- Amir M, Vora RS, Tafesh ZH, Jesudian A, Gupta V, Schwartz RE, Russo N, Danford CJ, Lau DTY, Brown RS, Jalan-Sakrikar N, Maiers JL, Sharma R, Fortune BE, Hilscher M, Aseem SO. Hepatology Highlights. Hepatology 2019, 70: 1497-1499. PMID: 31661168, DOI: 10.1002/hep.30995.
- Suri JS, Ezaz G, Lau DTY, Kulai TB, Malhi H, Tafesh ZH, Fortune B, Rosenblatt R, Brown RS, Pisa JF, Russo N, Hirsova P, Schwartz RE, Obaidullah Aseem S, Jalan-Sakrikar N, Gupta V. Hepatology Highlights. Hepatology 2019, 69: 2311-2314. PMID: 31141204, DOI: 10.1002/hep.30775.
- Mousa O, Malhi H, Schwartz RE, Kulai TB, Trivedi HD, Lau DTY, Shen NT, Brown RS, Hirsova P, Xu X, Nicholls HT, Pisa JF, Tafesh ZH, Fortune BE, Gupta V, Kostallari E, Russo N, Jesudian AB. Hepatology Highlights. Hepatology 2019, 69: 927-930. PMID: 30811657, DOI: 10.1002/hep.30569.
- Russo N, Brown RS, Shah SL, Krisko TI, Krumm CS, Nicholls HT, Mousa O, Malhi H, Schwartz RE, Lominadze Z, Rosenblatt R, Fortune BE, Pisa JF, Jesudian AB, Gupta V, Tafesh ZH. Hepatology Highlights. Hepatology 2019, 69: 469-472. PMID: 30695118, DOI: 10.1002/hep.30511.
- Russo N, Jesudian A, Shen NT, Brown RS, Sugiyama A, Nicholls HT, Pisa JF, Krisko TI, Rosenblatt R, Tafesh ZH, Fortune BE, Mousa O, Malhi H, Schwartz RE, Gupta V, Kulai TB, Malhi H. Hepatology Highlights. Hepatology 2019, 69: 1-4. PMID: 30618107, DOI: 10.1002/hep.30480.
- Gupta V, Rodrigues R, Nguyen D, Sauk J, Khalili H, Yajnik V, Ananthakrishnan AN. Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta‐analysis. Alimentary Pharmacology & Therapeutics 2015, 43: 52-60. PMID: 26541937, PMCID: PMC4673010, DOI: 10.1111/apt.13454.
- Fang Y, Gupta V, Karra R, Holdway JE, Kikuchi K, Poss KD. Translational profiling of cardiomyocytes identifies an early Jak1/Stat3 injury response required for zebrafish heart regeneration. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 13416-13421. PMID: 23901114, PMCID: PMC3746860, DOI: 10.1073/pnas.1309810110.
- Gupta V, Gemberling M, Karra R, Rosenfeld GE, Evans T, Poss KD. An Injury-Responsive Gata4 Program Shapes the Zebrafish Cardiac Ventricle. Current Biology 2013, 23: 1221-1227. PMID: 23791730, PMCID: PMC3759223, DOI: 10.1016/j.cub.2013.05.028.
- Gupta V, Poss KD. Clonally dominant cardiomyocytes direct heart morphogenesis. Nature 2012, 484: 479-484. PMID: 22538609, PMCID: PMC3340018, DOI: 10.1038/nature11045.
- Kikuchi K, Gupta V, Wang J, Holdway JE, Wills AA, Fang Y, Poss KD. tcf21+ epicardial cells adopt non-myocardial fates during zebrafish heart development and regeneration. Development 2011, 138: 2895-2902. PMID: 21653610, PMCID: PMC3119303, DOI: 10.1242/dev.067041.
- Yale Medicine, Digestive Diseases325 Riverside Ave325 Riverside AvenueWestport, CT 06880
- Yale Medicine, Digestive DiseasesYale Bariatric and Minimally Invasive Surgery2000 Post RoadFairfield, CT 06824
Biography
Vikas Gupta, MD, PhD, is a gastroenterologist who specializes in liver disease and medical weight loss management.
Growing up, Dr. Gupta had a unique perspective of medical education and training. His father switched careers and entered medical school when Dr. Gupta was about 7. “He wasn’t a full-fledged physician until I was in high school, and I got to watch the whole process,” he says. “It struck me as an intellectually interesting and rewarding career path.”
After medical school, Dr. Gupta considered specializing in cardiology, but during internal medical training, his exposure to patients with end-stage liver disease changed his mind.
“I found the physiology of this patient population really interesting and saw opportunities for clinical improvement,” he says. “When your liver doesn’t function well, it can affect your lungs, heart, kidneys, gastrointestinal tract, skin, and brain. By taking care of patients with liver disease, it keeps me thinking about the physiology of all organs.”
As clinical director of the Fatty Liver Disease Program, Dr. Gupta says a major piece of his job is medical weight management. “We are seeing so many patients with liver abnormalities that stem from fatty liver disease that we know will improve with weight loss,” he says. “We have a great team and resources to help patients achieve their weight loss goals. We want to help patients with fatty liver disease avoid developing end-stage liver disease.”
In the clinic, Dr. Gupta likes to keep it simple, “In medical training, we learn so much jargon that is not useful to patients,” he says. “I try to draw diagrams and simplify the terminology to make it easier for patients to understand.”
Titles
- Assistant Professor of Medicine (Digestive Diseases) and of Pathology
- Clinical Director of Yale Fatty Liver Disease Program, Internal Medicine
Education & Training
- FellowshipWeill Cornell Medical College (2020)
- ResidencyMassachusetts General Hospital (2016)
- InternshipMassachusetts General Hospital (2015)
- PhDDuke University School of Medicine (2014)
- MDDuke University School of Medicine (2014)
- BSPennsylvania State University, Biology (2007)
Additional Information
- Junior Faculty Samuel Kushlan Award: (2023)
- Early Career Investigator in Basic Science: AASLD (2020)
- Kellen Fellowship: (2019)
- Cani L, Gupta V, Kaufman J. BCL2 inhibition for multiple myeloma and AL amyloidosis. British Journal Of Haematology 2025 PMID: 40090369, DOI: 10.1111/bjh.20046.
- Nair R, Vu A, Freer A, Bhatia K, Wang D, Savani M, Matulis S, Lonial S, Jaye D, Boise L, Seo S, Corson T, Nooka A, Bhatt S, McBrayer S, Gupta V, Hu X, Barwick B, Reddi A, Shanmugam M. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood 2025, 145: 732-747. PMID: 39693611, DOI: 10.1182/blood.2024025690.
- Potdar S, Kapadia S, Azeem M, Radzievski R, Lakhani K, Joseph N, Kaufman J, Hofmeister C, Gupta V, Lonial S, Nooka A, Dhodapkar K, Dhodapkar M. Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myeloma. Blood Advances 2025 PMID: 39913930, DOI: 10.1182/bloodadvances.2024015680.
- Dutta R, Thibaud S, Leshchenko V, Ram M, Melnekoff D, Bhalla S, Restrepo P, Gupta V, Barwick B, Newman S, McCafferty J, Hantash F, Nooka A, Cho H, Richard S, Rodriguez C, Rossi A, Sanchez L, Chari A, Boise L, Jagannath S, Richter J, Parekh S, Laganà A. Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma. Blood Neoplasia 2024, 1: 100049. DOI: 10.1016/j.bneo.2024.100049.
- Bollinger B, Cotter R, Deng Y, Ilagan-Ying Y, Gupta V. Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease. Digestive Diseases And Sciences 2024, 70: 378-385. PMID: 39604664, DOI: 10.1007/s10620-024-08724-y.
- Joseph N, Gupta S, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A. Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 7870-7870. DOI: 10.1182/blood-2024-211988.
- Gu L, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 3780. DOI: 10.1182/blood-2024-211474.
- Allada S, Gupta V, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Joseph N. Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers. Blood 2024, 144: 7861. DOI: 10.1182/blood-2024-210996.
- Matulis S, Chavez R, Owens R, Wiita A, Shanmugam M, De Matos Simoes R, Mitsiades C, Joseph N, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Gupta V, Licht J, Barwick B, Boise L. Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2. Blood 2024, 144: 4663-4663. DOI: 10.1182/blood-2024-210441.
- Joseph N, Kaufman J, Hofmeister C, Gupta V, Burton B, Pruitt R, Nooka A, Dhodapkar M, Lonial S. Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM). Blood 2024, 144: 1983-1983. DOI: 10.1182/blood-2024-210335.
- Cani L, Scott S, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies. Blood 2024, 144: 3311. DOI: 10.1182/blood-2024-206155.
- Shivaram S, Yan H, Tang H, Anderson H, Kaddoura M, Wiedmeier-Nutor J, Tian S, Howe M, Bolarinwa A, Zepeda Mendoza C, Gupta V, Lehman S, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Maura F, Kumar S, Baughn L. The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma. Blood 2024, 144: 4635-4635. DOI: 10.1182/blood-2024-205385.
- Varga C, Robinson M, Gupta V, Hofmeister C, Nooka A, Kaufman J, Dhodapkar M, Lonial S, Borden S, Ferreri C, Paul B, Atrash S, Bhutani M, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes. Blood 2024, 144: 4702-4702. DOI: 10.1182/blood-2024-204388.
- Kaddoura M, Wiedmeier-Nutor J, Gupta V, Ziccheddu B, Shivaram S, Tang H, Fonseca R, Durante M, Matulis S, Jelinek T, Landgren O, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Kumar S, Maura F, Baughn L. Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax. Blood 2024, 144: 249. DOI: 10.1182/blood-2024-204071.
- Hofmeister C, Gupta V, Joseph N, Lonial S, Dhodapkar M, Nooka A, Kaufman J. A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy. Blood 2024, 144: 4672. DOI: 10.1182/blood-2024-203485.
- Hofmeister C, Gupta V, Kaufman J, Nooka A, Joseph N, Lonial S, Dhodapkar M. A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma. Blood 2024, 144: 255-255. DOI: 10.1182/blood-2024-202102.
- Hofmeister C, Zhang M, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Sborov D. Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting. Blood 2024, 144: 5152-5152. DOI: 10.1182/blood-2024-202100.
- Najarro G, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Hofmeister C. Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade. Blood 2024, 144: 5142-5142. DOI: 10.1182/blood-2024-202078.
- Householder S, Loza A, Gupta V, Doolittle B. Using Panel Management to Identify Adult Patients With High-Risk Metabolic Dysfunction–Associated Steatotic Liver Disease/Metabolic Dysfunction–Associated Steatohepatitis Fibrosis in a Primary Care Clinic: A Pilot Study. The Permanente Journal 2024, 28: 38-47. PMID: 39444281, PMCID: PMC11648331, DOI: 10.7812/tpp/24.094.
- Matulis S, Barwick B, Bombin S, Ackley J, Gupta V, Hill G, Green D, Riddell S, Lonial S, Dhodapkar M, Boise L. P-234 Autocrine IL6 Signaling in Stromal Cells in Multiple Myeloma Influences the Bone Marrow Microenvironment. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s173. DOI: 10.1016/s2152-2650(24)02137-2.
- Morffi R, Pruitt R, Nguyen K, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Kaufman J, Nooka A. P-179 Rates of Successful Diagnostic Clonal Identification (ID) With Adaptive clonoSEQ®. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s141-s142. DOI: 10.1016/s2152-2650(24)02082-2.
- Joseph N, Pruitt R, Gupta V, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Kaufman J. P-342 Impact of Achieving
DOI: 10.1016/s2152-2650(24)02244-4. - Joseph N, Kaufman J, Gupta V, Hofmeister C, Dhodapkar M, Scott S, Dicamillo S, Roberts D, Lonial S, Nooka A. OA-51 Efficacy of Dara-RVD Induction Therapy in Newly Diagnosed Myeloma (NDMM) Patients ≥65 Years of Age. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s32. DOI: 10.1016/s2152-2650(24)01892-5.
- Scott S, Roberts D, Gupta V, Joseph N, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. NSO-06 Protocol for Outpatient Administration of Multiple Myeloma Bispecific Antibodies Step-Up Dosing. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s282. DOI: 10.1016/s2152-2650(24)02331-0.
- Varga C, Robinson M, Ehsan H, Roberts D, Dicamillo S, Gupta V, Borden S, Bhutani M, Paul B, Atrash S, Ferreri C, Nooka A, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience. Transplantation And Cellular Therapy 2024, 30: s377-s378. DOI: 10.1016/j.jtct.2023.12.528.
- Singh S, Budiman T, Redmond D, Gupta V. Modulation of canonical Wnt signaling regulates peribiliary mesenchymal identity during homeostasis and injury. Hepatology Communications 2024, 8: e0368. PMID: 38251878, PMCID: PMC10805418, DOI: 10.1097/hc9.0000000000000368.
- Scott S, Marin E, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer Journal 2023, 13: 191. PMID: 38114481, PMCID: PMC10730907, DOI: 10.1038/s41408-023-00963-y.
- Juarez D, Buono R, Matulis S, Gupta V, Duong M, Yudiono J, Paul M, Mallya S, Diep G, Hsin P, Lu A, Suh S, Dong V, Roberts A, Leverson J, Jalaluddin M, Liu Z, Bueno O, Boise L, Fruman D. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitors. Cancer Research Communications 2023, 3: 2497-2509. PMID: 37956312, PMCID: PMC10704957, DOI: 10.1158/2767-9764.crc-23-0350.
- Lewis J, Shebelut C, Attieh M, Horwath M, Khanna A, Al-Rusan O, Ponnatt T, Smith G, Gutman D, Gupta V, Aljudi A, Cooper L, Jaye D. Machine Learning Models Predict Molecular Genetic Subtypes of Multiple Myeloma from Whole-Slide Bone Marrow Aspirate Smears. Blood 2023, 142: 7158. DOI: 10.1182/blood-2023-190686.
- Kaufman J, Joseph N, Gupta V, Dicamillo S, Roberts D, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Boise L. Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma. Blood 2023, 142: 4699. DOI: 10.1182/blood-2023-181783.
- Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.
- Nooka A, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Burton B, Ahmed H, Linton D, Cortoos A, Lin T, Labotka R, Noga S, Kaufman J, Lonial S. A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study. Blood 2023, 142: 4764. DOI: 10.1182/blood-2023-190871.
- Marin E, Scott S, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration. Blood 2023, 142: 2008. DOI: 10.1182/blood-2023-189878.
- Singh S, Lian Q, Budiman T, Taketo M, Simons B, Gupta V. Heterogeneous murine peribiliary glands orchestrate compartmentalized epithelial renewal. Developmental Cell 2023, 58: 2732-2745.e5. PMID: 37909044, PMCID: PMC10842076, DOI: 10.1016/j.devcel.2023.10.004.
- Bram Y, Nguyen DT, Gupta V, Park J, Richardson C, Chandar V, Schwartz RE. Cell and Tissue Therapy for the Treatment of Chronic Liver Disease. Annual Review Of Biomedical Engineering 2021, 23: 1-30. PMID: 33974812, PMCID: PMC8864721, DOI: 10.1146/annurev-bioeng-112619-044026.
- Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, Tang X, Zhu J, Zhao Z, Jaffré F, Zhang T, Kim TW, Harschnitz O, Redmond D, Houghton S, Liu C, Naji A, Ciceri G, Guttikonda S, Bram Y, Nguyen DT, Cioffi M, Chandar V, Hoagland DA, Huang Y, Xiang J, Wang H, Lyden D, Borczuk A, Chen HJ, Studer L, Pan FC, Ho DD, tenOever BR, Evans T, Schwartz RE, Chen S. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell 2020, 27: 125-136.e7. PMID: 32579880, PMCID: PMC7303620, DOI: 10.1016/j.stem.2020.06.015.
- Gupta V, Gupta I, Park J, Bram Y, Schwartz RE. Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells. Gastroenterology 2020, 159: 624-638.e9. PMID: 32289375, PMCID: PMC8204800, DOI: 10.1053/j.gastro.2020.03.075.
- Amir M, Vora RS, Tafesh ZH, Jesudian A, Gupta V, Schwartz RE, Russo N, Danford CJ, Lau DTY, Brown RS, Jalan-Sakrikar N, Maiers JL, Sharma R, Fortune BE, Hilscher M, Aseem SO. Hepatology Highlights. Hepatology 2019, 70: 1497-1499. PMID: 31661168, DOI: 10.1002/hep.30995.
- Suri JS, Ezaz G, Lau DTY, Kulai TB, Malhi H, Tafesh ZH, Fortune B, Rosenblatt R, Brown RS, Pisa JF, Russo N, Hirsova P, Schwartz RE, Obaidullah Aseem S, Jalan-Sakrikar N, Gupta V. Hepatology Highlights. Hepatology 2019, 69: 2311-2314. PMID: 31141204, DOI: 10.1002/hep.30775.
- Mousa O, Malhi H, Schwartz RE, Kulai TB, Trivedi HD, Lau DTY, Shen NT, Brown RS, Hirsova P, Xu X, Nicholls HT, Pisa JF, Tafesh ZH, Fortune BE, Gupta V, Kostallari E, Russo N, Jesudian AB. Hepatology Highlights. Hepatology 2019, 69: 927-930. PMID: 30811657, DOI: 10.1002/hep.30569.
- Russo N, Brown RS, Shah SL, Krisko TI, Krumm CS, Nicholls HT, Mousa O, Malhi H, Schwartz RE, Lominadze Z, Rosenblatt R, Fortune BE, Pisa JF, Jesudian AB, Gupta V, Tafesh ZH. Hepatology Highlights. Hepatology 2019, 69: 469-472. PMID: 30695118, DOI: 10.1002/hep.30511.
- Russo N, Jesudian A, Shen NT, Brown RS, Sugiyama A, Nicholls HT, Pisa JF, Krisko TI, Rosenblatt R, Tafesh ZH, Fortune BE, Mousa O, Malhi H, Schwartz RE, Gupta V, Kulai TB, Malhi H. Hepatology Highlights. Hepatology 2019, 69: 1-4. PMID: 30618107, DOI: 10.1002/hep.30480.
- Gupta V, Rodrigues R, Nguyen D, Sauk J, Khalili H, Yajnik V, Ananthakrishnan AN. Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta‐analysis. Alimentary Pharmacology & Therapeutics 2015, 43: 52-60. PMID: 26541937, PMCID: PMC4673010, DOI: 10.1111/apt.13454.
- Fang Y, Gupta V, Karra R, Holdway JE, Kikuchi K, Poss KD. Translational profiling of cardiomyocytes identifies an early Jak1/Stat3 injury response required for zebrafish heart regeneration. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 13416-13421. PMID: 23901114, PMCID: PMC3746860, DOI: 10.1073/pnas.1309810110.
- Gupta V, Gemberling M, Karra R, Rosenfeld GE, Evans T, Poss KD. An Injury-Responsive Gata4 Program Shapes the Zebrafish Cardiac Ventricle. Current Biology 2013, 23: 1221-1227. PMID: 23791730, PMCID: PMC3759223, DOI: 10.1016/j.cub.2013.05.028.
- Gupta V, Poss KD. Clonally dominant cardiomyocytes direct heart morphogenesis. Nature 2012, 484: 479-484. PMID: 22538609, PMCID: PMC3340018, DOI: 10.1038/nature11045.
- Kikuchi K, Gupta V, Wang J, Holdway JE, Wills AA, Fang Y, Poss KD. tcf21+ epicardial cells adopt non-myocardial fates during zebrafish heart development and regeneration. Development 2011, 138: 2895-2902. PMID: 21653610, PMCID: PMC3119303, DOI: 10.1242/dev.067041.
- Yale Medicine, Digestive Diseases325 Riverside Ave325 Riverside AvenueWestport, CT 06880
- Yale Medicine, Digestive DiseasesYale Bariatric and Minimally Invasive Surgery2000 Post RoadFairfield, CT 06824
- Yale Medicine, Digestive Diseases325 Riverside Ave325 Riverside AvenueWestport, CT 06880
- Yale Medicine, Digestive DiseasesYale Bariatric and Minimally Invasive Surgery2000 Post RoadFairfield, CT 06824